Innovent Biologics's market cap is currently $64.38B. The company's EPS TTM is HK$-0.876; its P/E ratio is ―; Innovent Biologics is scheduled to report earnings on March 26, 2025, and the estimated EPS forecast is HK$-0.25. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Income Statement
Total Revenue	¥ 6.21B	¥ 4.56B	¥ 4.27B	¥ 3.84B	¥ 1.05B
Gross Profit	¥ 4.40B	¥ 3.63B	¥ 3.70B	¥ 3.46B	¥ 922.65M
Operating Income	¥ -1.68B	¥ -2.07B	¥ -3.11B	¥ -820.14M	¥ -1.66B
EBITDA	¥ -660.68M	¥ -1.75B	¥ -2.37B	¥ -704.74M	¥ -1.57B
Net Income	¥ -1.03B	¥ -2.18B	¥ -3.14B	¥ -998.42M	¥ -1.78B
Balance Sheet
Cash & Short-Term Investments	¥ 10.97B	¥ 8.26B	¥ 7.94B	¥ 8.05B	¥ 4.70B
Total Assets	¥ 20.63B	¥ 17.59B	¥ 16.24B	¥ 11.83B	¥ 7.23B
Total Debt	¥ 3.62B	¥ 3.23B	¥ 2.50B	¥ 1.21B	¥ 865.09M
Net Debt	¥ -6.43B	¥ 2.21B	¥ 1.14B	¥ -69.61M	¥ -1.56B
Total Liabilities	¥ 8.10B	¥ 6.86B	¥ 5.91B	¥ 3.06B	¥ 2.47B
Stockholders' Equity	¥ 12.53B	¥ 10.73B	¥ 10.33B	¥ 8.78B	¥ 4.76B
Cash Flow
Free Cash Flow	¥ -1.24B	¥ -3.30B	¥ -3.87B	¥ -1.08B	¥ -2.03B
Operating Cash Flow	¥ 147.81M	¥ -1.92B	¥ -2.02B	¥ -307.69M	¥ -1.66B
Investing Cash Flow	¥ -998.66M	¥ -1.44B	¥ -2.70B	¥ -5.18B	¥ -2.57B
Financing Cash Flow	¥ 2.59B	¥ 2.89B	¥ 5.00B	¥ 4.91B	¥ 2.11B

Currency in CNY

Innovent Biologics Earnings and Revenue History

Income Statement >

Innovent Biologics Debt to Assets

Balance Sheet >

Innovent Biologics Cash Flow

Cash Flow >

Innovent Biologics Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing